Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic

Best Pharmaceutical Stocks to Buy Now (2025)

Top pharmaceutical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best pharmaceutical stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best pharma stocks to buy right now are:

Amneal Pharmaceuticals (NASDAQ:AMRX) is the #1 top pharmaceutical stock out of 76 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 37, which is 10 points higher than the pharmaceutical industry average of 27.

AMRX passed 12 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 10.93% over the past year, overperforming other pharmaceutical stocks by 33 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $14.00, an upside of 43.74% from Amneal Pharmaceuticals's current stock price of $9.74.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Indivior (NASDAQ:INDV) is the #2 top pharmaceutical stock out of 76 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Indivior (NASDAQ:INDV) is: Value: B, Growth: C, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: C.

Indivior (NASDAQ:INDV) has a Due Diligence Score of 26, which is -1 points lower than the pharmaceutical industry average of 27. Although this number is below the industry average, our proven quant model rates INDV as a "A".

INDV passed 8 out of 33 due diligence checks and has average fundamentals. Indivior has seen its stock return 138.68% over the past year, overperforming other pharmaceutical stocks by 161 percentage points.

Indivior has an average 1 year price target of $27.33, an upside of 20.04% from Indivior's current stock price of $22.77.

Indivior stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Indivior, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Ani Pharmaceuticals (NASDAQ:ANIP) is the #3 top pharmaceutical stock out of 76 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ani Pharmaceuticals (NASDAQ:ANIP) is: Value: C, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: C, and AI: B.

Ani Pharmaceuticals (NASDAQ:ANIP) has a Due Diligence Score of 22, which is -5 points lower than the pharmaceutical industry average of 27. Although this number is below the industry average, our proven quant model rates ANIP as a "A".

ANIP passed 8 out of 33 due diligence checks and has weak fundamentals. Ani Pharmaceuticals has seen its stock return 73.58% over the past year, overperforming other pharmaceutical stocks by 96 percentage points.

Ani Pharmaceuticals has an average 1 year price target of $94.50, a downside of -3.13% from Ani Pharmaceuticals's current stock price of $97.55.

Ani Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Ani Pharmaceuticals, 25% have issued a Strong Buy rating, 50% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

Viatris (NASDAQ:VTRS) has an annual dividend yield of 5.02%, which is 3 percentage points higher than the pharmaceutical industry average of 2.33%. Viatris's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Viatris's dividend has shown consistent growth over the last 10 years.

Viatris's dividend payout ratio of -16.6% indicates that its high dividend yield might not be sustainable for the long-term.

Perrigo Co (NYSE:PRGO) has an annual dividend yield of 4.01%, which is 2 percentage points higher than the pharmaceutical industry average of 2.33%. Perrigo Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Perrigo Co's dividend has shown consistent growth over the last 10 years.

Perrigo Co's dividend payout ratio of -195.2% indicates that its high dividend yield might not be sustainable for the long-term.

Kamada (NASDAQ:KMDA) has an annual dividend yield of 2.84%, which is 1 percentage points higher than the pharmaceutical industry average of 2.33%.

Kamada's dividend payout ratio of 60.6% indicates that its dividend yield is sustainable for the long-term.

Pharmaceutical stocks were up 0.14% in the last day, and down -0.58% over the last week.

We couldn't find a catalyst for why pharmaceutical stocks are up.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued pharmaceutical stocks right now are:

Bausch Health Companies (NYSE:BHC) is the most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 57, which is 37 points higher than the pharmaceutical industry average of 20. It passed 4 out of 7 valuation due diligence checks.

Bausch Health Companies's stock has dropped -3.14% in the past year. It has overperformed other stocks in the pharmaceutical industry by 19 percentage points.

Emergent Biosolutions (NYSE:EBS) is the second most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Emergent Biosolutions has a valuation score of 14, which is -6 points higher than the pharmaceutical industry average of 20. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates EBS a Valuation Rating of "A".

Emergent Biosolutions's stock has gained 8% in the past year. It has overperformed other stocks in the pharmaceutical industry by 30 percentage points.

Siga Technologies (NASDAQ:SIGA) is the third most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Siga Technologies has a valuation score of 86, which is 66 points higher than the pharmaceutical industry average of 20. It passed 6 out of 7 valuation due diligence checks.

Siga Technologies's stock has gained 12.52% in the past year. It has overperformed other stocks in the pharmaceutical industry by 35 percentage points.

47.62% of pharmaceutical stocks rated by analysts are a buy right now. On average, analysts expect pharmaceutical stocks to rise by 32.44% over the next year.

16.07% of pharmaceutical stocks have a Zen Rating of A (Strong Buy), 17.86% of pharmaceutical stocks are rated B (Buy), 50% are rated C (Hold), 14.29% are rated D (Sell), and 1.79% are rated F (Strong Sell).